SET_ER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer.

ABSTRACT: There is a clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diagnostic potential to measure both transcriptional activity and functional mutation. We developed the SET_ER/PR index to measure gene expression microarray probe sets that were correlated with hormone receptors (ESR1 and PGR) and robust to preanalytical and analytical influences. We tested SET_ER/PR index in biopsies of metastastic HR+/HER2- breast cancer against the treatment outcomes in 140 patients. Then we customized the SET_ER/PR assay to measure 18 informative, 10 reference transcripts, and sequence the ligand-binding domain (LBD) of ESR1

SUBMITTER: Sinn BV 

PROVIDER: S-EPMC6542807 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature